A Clinical Study to Map the HLA Genomic Region in the Greek Population

Launched by ATHENS LIFETECH PARK · Jan 25, 2024

Keywords

ClinConnect Summary

The GENESIS clinical study aims to better understand a specific part of our genes called the HLA genomic region in the Greek population. Researchers believe that this region may be linked to various health conditions, such as respiratory diseases, heart problems, kidney issues, and more. By studying how this genetic area relates to these diseases, they hope to gather important information that could improve health care for people in Greece.

To join this study, participants must be at least 18 years old, have a Greek social security number, and be visiting a hospital or clinic in Greece for regular health care. They will need to agree to provide written consent to participate. However, individuals who have received certain types of transplants or blood transfusions recently, or who cannot give consent due to serious health issues, will not be eligible. Participants can expect to provide a simple saliva sample and help contribute to advancing medical knowledge, which may benefit future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• The study will include adult subjects (age ≥ 18) that:
• • possess a Greek social security number and are visiting hospitals/clinics, and/or other private laboratory institutions (incl. clinics and health care groups) as part of standard clinical practice in Greece,
• • are willing and able to provide written informed consent to participate in the study according to the study protocol.
• Exclusion Criteria:
• • Subjects not able to provide written informed consent (e.g. ICU patients, mental illness patients, lack of legal capacity).
• * Subjects who have had an allogeneic (non-self-donor):
• • bone marrow transplant
• • stem cell transplant
• • blood transfusion less than two weeks prior to buccal swab sample collection
• • liver transplant
• • Subjects who participated in an interventional clinical trial in the past that according to the subject's physician opinion might have had an impact on their HLA genome.